CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, a leader in the development of innovative gene therapies for severe genetic disorders, announced today that Nick Leschly, CEO of bluebird bio, is scheduled to present at the UBS Global Life Sciences Conference on Thursday, September 20, 2012 at 10:00AM ET in New York City.
